MAVS Mouse anti-Human, Clone: OTI9C4, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA526963
DescriptionTwo distinct signaling pathways activate the host innate immunity against viral infection. One pathway is reliant on members of the Toll-like receptor (TLR) family while the other uses the RNA helicase RIG-I as a receptor for intracellular viral double-stranded RNA as a trigger for the immune response. VISA is a mitochondrial membrane protein that was identified as a critical component in the IFN-b signaling pathways that recruits IRF-3 to RIG-I, leading to its activation and that of NF-kappa-B. VISA is also thought to interact with other components of the innate immune pathway such as the TLR adapter protein TRIF, TRAF2 and TRAF6. VISA also interacts with the IKK-a, IKK-b and IKK-iota kinases through its C-terminal region. Cleavage of this region by the Hepatitis C virus (HCV) protease allows HCV to escape the host immune system. At least three isoforms of VISA are known to exist.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3|
|CARD adapter inducing interferon beta; CARD adapter inducing interferon-beta; CARD adaptor inducing IFN-beta; IFN-B promoter stimulator 1; interferon beta promoter stimulator protein 1; interferon-beta promoter stimulator protein 1; mitochondrial anti-viral signaling protein; mitochondrial antiviral-signaling protein; putative NF-kappa-B-activating protein 031N; virus-induced signaling adapter variant 1b; virus-induced signaling adaptor variant 1a; virus-induced-signaling adapter|
|-20° C, Avoid Freeze/Thaw Cycles|
|Immunohistochemistry (Paraffin), Western Blot|
|Human recombit protein fragment corresponding to amino acids 1-247 of MAVS produced in E.coli|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok